The case in front of me: ecnoglutide · Changsha.
I want to decide this in advance so that I am not deciding it under pressure later.
Assume I will follow the plan I write down, so I would like it to be a good one.
What should I decide now, and what should I defer?
The question to ask is not whether a vendor is good but what evidence exists, of what kind, about which lots, from whom. Reputation is a compression of that evidence and it compresses badly.
Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.
Concretely, a defensible group-buy structure has three properties: the material is tested before it is split, the test is paid for from the pool rather than by the organiser, and the split is documented with photographs and a per-participant record of lot, volume and date. If any participant can reconstruct what they received from the records, a later dispute is resolvable. If not, it is not.
Where VendorInvestigate has documented verification processes, the value is in the audit trail rather than in the badge, and reading the process description is more informative than reading the outcome.
Worth being explicit that this site sells nothing, is not affiliated with any supplier, and has no financial relationship with any vendor discussed. Vendor storefronts are linked from the vendor directory, marked nofollow and sponsored.
Assume no recourse and plan accordingly. That assumption is both prudent and, in this context, accurate.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe structural problem with a group buy is that the organiser typically holds both the money and the material, which means there is no point at which any participant has recourse. That is solvable, and it is solved by design rather than by trust.
The difference between a batch certificate and a vial certificate is a difference in what is being claimed. A batch certificate says "we tested some vials from this lot". A vial certificate says "we tested this vial". Neither is worthless; only one of them is about the object in your hand, and the gap between them is a sampling assumption nobody has quantified.
On declarations: the accurate description of a research reference material is a research reference material, and accuracy is both the legal position and the practical one. A declaration that misdescribes the contents converts a customs question into a different kind of question, and it does so on a document with your name on it.
I would resist treating a long track record as evidence of current quality. Suppliers change synthesis partners, fill sites and staff, and a 2024 result is weak evidence about a 2026 lot.
Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.